The aim of this study was to identify the risk factors for acute graft-versus-host disease (aGVHD) in children transplanted from a matched-sibling donor (MSD) or an unrelated donor (UD). In all, 87 children consecutively underwent allogeneic bone marrow transplantation (BMT) from MSD (n=36), and UD (n=51). GVHD prophylaxis included CsA alone (n=33) or with MTX (n=51). ATG was added in UD-BMT and thalassemic recipients. CsA whole-blood concentrations were measured by EMIT and the dosing regimen was monitored by Bayesian pharmacokinetic modelling. Trough blood concentration (TBC) during the first 2 weeks post transplantation was lower in children who developed grade II–IV aGVHD than those developing no GVHD or only grade I (57±9 vs 94±8 ng/ml, P=0.007), whereas peak blood concentration and area under concentration curve vs time were similar in both groups. TBC <85 ng/ml and ‘use of MTX’ were associated with aGVHD in MSD-SCT (P=0.003 and 0.007, respectively) as well as in UD-SCT (P=0.006 and 0.003). Donor age ⩾8 years was significant only in MSD-BMT. Our results have shown the significant decisive role of pharmacological factors such as CSA TBC or use of MTX in the occurrence of GVHD in MSD as well as in UD paediatric BMT.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
BMC Pediatrics Open Access 11 May 2020
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Locatelli F, Uderzo C, Dini G et al. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 1993; 12: 627–633.
Locatelli F, Zecca M, Rondelli R et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukaemia given HLA-identical sibling bone marrow transplantation: results of a randomised trial. Blood 2000; 95: 1572–1579.
Casper J, Camitta B, Truitt R et al. Unrelated bone marrow donor transplants for children with leukaemia or myelodysplasia. Blood 1995; 85: 2354–2363.
Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247–3256.
Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574–578.
Davies SM, Wagner JE, Shu XO et al. Unrelated donor bone marrow transplantation for children with acute leukaemia. J Clin Oncol 1997; 15: 557–565.
Kondo M, Kojima S, Horibe K et al. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant 2001; 27: 727–730.
Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of bone marrow grafts. N Engl J Med 1979; 300: 1068–1073.
Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host-disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukaemia. Blood 1989; 73: 1720–1728.
Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukaemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Gratwohl A, Hermans J, Apperley J et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukaemia. Working party chronic leukaemia of the european group for blood and marrow transplantation. Blood 1995; 86: 813–818.
Ringden O, Labopin M, Gluckman E et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921–992.
Ringden O, Hermans J, Labopin M et al. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leukemia Lymphoma 1996; 24: 71–79.
Bortin MM, Rimm AA . Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA 1977; 238: 591–600.
Bortin MM, Rimm AA . Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. JAMA 1981; 245: 1132–1139.
Zwaan FE, Hermans J . Bone marrow transplantation for leukemia: European results in 264 cases. Exp Hematol 1982; 10: 47–54.
Ramsay NKC, Kersey JH, Robison LL et al. A randomized study of the prevention of acute graft-versus -host disease. New Engl J Med 1982; 306: 392–397.
Bross DS, Tutschka PJ, Farmer ER et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63: 1265–1270.
Bortin MM . Risk factors for acute graft-versus-host disease. Exp Hematol 1985; 13: 406–415.
Ringden O, Nilsson B . Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39–44.
Atkinson K, Farrel C, Chapman G et al. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulation in the donor marrow inoculum. Br J Haematol 1986; 63: 231–239.
Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397–406.
Gratama JW, Stijnen T, Weiland HT et al. Herpes-virus immunity and acute graft-versus-host disease. Lancet 1987; i: 471–474.
Boström L, Ringdén O, Sundberg B et al. Pretransplant herpes virus serology and acute GVHD. Transplantation 1988; 46: 548–552.
Boström L, Ringdén O, Gratama JW et al . A role of herpes virus serology for the development of acute graft-versus-host disease. Bone Marrow Transplant 1990; 5: 321–326.
Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838–1845.
Hägglund H, Bostrom L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplantation. Bone Marrow Transplant 1995; 16: 747–753.
Storb R, Deeg HJ, Farewall V et al. Marrow transplantation for severe aplastic anaemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119–124.
Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukaemia. N Engl J Med 1986; 314: 729–735.
Yee GC, Self SG, Mc Guire TR et al. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65–70.
Przepiorka D, Shapiro S, Schwingammer TL et al. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 1991; 7: 461–465.
Ghalie R, Fitzsimmons WE, Weinstein A et al. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ann Pharmacother 1994; 28: 379–383.
Eisner MD, August CS . Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663–668.
Souillet G, Rey S, Bertrand Y et al. Outcome of unrelated bone marrow donor searches in 174 children resulting in 45 patients transplanted in the HLA-matched and-mismatched situation. Bone Marrow Transplant 2000; 26: 31–43.
Laboratory of Applied Pharmacokinetics. USC* Pack P.C. Collection Clinical Research Programs. Los Angeles: University of Southern California, School of Medicine, 1995, version 10.7.
Jelliffe RW, Schumitzky A, Van Guilder M et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380–393.
Jelliffe RW . Effect of assumptions concerning assay error patterns upon pharmacokinetic parameter values and model behavior. J Vet Pharmacol Ther 1994; 17: 105–109.
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443–447.
Hows J, Bradley BA, Gore S et al. Prospective evaluation of unrelated donor bone marrow transplantation. The international Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1993; 12: 371–380.
Grevel J, Welsh MS, Kahan BD . Cyclosporine monitoring in renal transplantation : area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11: 246–248.
About this article
Cite this article
Martin, P., Bleyzac, N., Souillet, G. et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 32, 881–887 (2003). https://doi.org/10.1038/sj.bmt.1704239
- acute GVHD
- risk factor
This article is cited by
BMC Pediatrics (2020)
Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis
Bone Marrow Transplantation (2016)
Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience
International Journal of Hematology (2013)
Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model
Pharmaceutical Research (2011)
Bone Marrow Transplantation (2010)